Építés alatt – nem éles oldal
Belépés
Toborzás még nem indult1. fázis

Phase I Study to Evaluate Single and Multiple Oral Doses of HW281171 Tablets in Healthy Participants

A legfontosabb adatok

Ki végzi
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
Hol
Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toborzás még nem indult
Fázis
1. fázis
Résztvevők
80 fő, tervezett
Kezdés
2026. nov. 18.
Várható befejezés
2027. szept.
A vizsgálat típusa
Beavatkozással járó, 6 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • HW281171 tablets
  • Placebo tablets
A regiszteradat frissítve
2026. november 13.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for healthy adults to test the safety of HW281171 tablets and how the body handles them. Single and repeated doses are tested, some with food.

Életkor
18 to 45 years
Nem
Men and women. Each sex has at least 3 participants.
Korábbi kezelés
People who took certain medicines or other treatments named in the protocol cannot join. People who were in a drug or device trial within 90 days before screening cannot join.
Biomarker vagy leletérték
Women must weigh ≥45.00 kg (99 lb), men ≥50.00 kg (110 lb). BMI must be 19.0 to 26.0 kg/m^2. Tests for HIV, hepatitis B, hepatitis C and syphilis must be negative.

A részvétel fő kizáró okai

  • Drug or food allergy, or allergy to two or more substances
  • Serious or long-term illness of the heart, hormones, nerves, gut, lungs, blood, immune system or mind
  • Pregnancy or breastfeeding
  • Drug abuse, smoking more than 5 cigarettes a day, or more than 14 alcohol units a week
  • Blood donation or blood loss of ≥400 ml, or major injury or surgery, within 3 months

Ez a vizsgálat csak egészséges résztvevőket keres. A regiszter mondata, amelyen ez alapul: * Healthy male and female participants aged 18 to 45 years (inclusive), with no less than 3 participants of a single gender.

A regiszter feltételei, szó szerint

Mind a 23 feltétel megnézéseKevesebb

Ki vehet részt

  • Participants sign the informed consent form prior to the initiation of any study procedures
  • Healthy male and female participants aged 18 to 45 years (inclusive), with no less than 3 participants of a single gender
  • Female participants have a body weight of ≥45.00 kg, male participants have a body weight of ≥50.00 kg, and the body mass index (BMI) ranges from 19.0 to 26.0 kg/m\^2 (inclusive)
  • Participants whose vital signs, physical examination, 12-lead electrocardiogram, laboratory tests, abdominal B-ultrasound and posteroanterior chest X-ray results at screening or on Day -1 are judged by the Investigator to be normal or abnormal without clinical significance
  • Participants agree to have no fertility plan and no sperm/egg donation plan from the time of signing the informed consent form until 3 months after study withdrawal, and are willing to practice abstinence or use highly effective contraceptive methods during this period
  • Participants can communicate well with the Investigator, understand and comply with all requirements of this study, and fully understand the study purpose, nature, methods and potential Adverse Events

Ki nem vehet részt

  • Participants with a history of drug or food allergy, allergic diseases, or allergic diathesis (allergic to two or more substances), or with confirmed allergy to any component or analogue of the investigational product
  • Female participants who are pregnant, lactating at screening or during the trial, or have a pregnancy test result above the upper limit of normal, or have had unprotected sexual intercourse within 2 weeks before screening
  • Participants with prior or concomitant medications/non-drug interventions specified in the protocol
  • Participants who have participated in any clinical trial of drugs or medical devices within 90 days before screening (participation in a clinical trial is defined as receiving or using the investigational drug/device)
  • Participants with severe trauma or surgical operation within 3 months before screening; participants who plan to receive surgery during the trial or within two weeks after trial completion
  • Participants who have donated blood or experienced a total blood loss of ≥400 ml within 3 months before the first dose
  • Participants with a smoking history within 3 months before screening (average daily consumption >5 cigarettes), or who cannot stop using any tobacco products during the trial
  • Participants with an average weekly alcohol intake of more than 14 alcohol units within 3 months before screening (1 alcohol unit is approximately 360 ml beer, or 45 ml spirits with 40 Percentage alcohol content, or 150 ml wine), or positive alcohol breath test, or who cannot abstain from alcohol during the trial
  • Participants consuming excessive tea, coffee or caffeinated beverages on average every day (more than 8 cups, 1 cup = 250 ml) within 48 hours before the first dose, or who cannot stop consuming tea, coffee or caffeinated beverages during the trial; participants who have consumed special diets within 48 hours before the first dose (including pitaya, mango, lime, pomelo, carambola, orange, grapefruit or grapefruit products and other fruits or corresponding juices that may affect drug metabolism), or other special diets affecting drug absorption, distribution, metabolism or excretion
  • Participants with any past or current clinically significant severe or chronic diseases of the circulatory, endocrine, nervous, digestive, respiratory, hematological, immune, psychiatric systems or metabolic disorders, or any other diseases judged by the investigator that may interfere with trial results
  • Participants with a history of gastrointestinal, hepatic or renal diseases affecting drug absorption or metabolism, or known or suspected diseases affecting drug intake, transport, absorption, distribution, metabolism or excretion; participants who have undergone surgeries affecting drug absorption or metabolism (appendectomy excluded)
  • Participants with a history of drug abuse, drug dependence, or positive drug screening results
  • Participants with positive results for any of human immunodeficiency virus antibody, hepatitis B virus surface antigen, hepatitis C virus antibody, or treponema pallidum specific antibody
  • Participants with abnormal examination results specified in the protocol at screening or on Day -1
  • Participants with difficult venous access and intolerance to venipuncture
  • Participants with special dietary requirements and unable to follow the unified diet
  • Participants with other factors judged by the investigator to be unsuitable for participating in the clinical trial

Nézd meg, megfelelhetsz-e

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 45 év között vagy?

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This phase 1 study aims to evaluate the safety, tolerability and pharmacokinetic profiles of HW281171 in healthy Participants. The study consists of three parts: Part A (Single-Dose Escalation Study), Part B (Food Effect and Metabolite Study), and Part C (Multiple-Dose Escalation Study).

A vizsgálat 6 csoportja

  • Part A:HW281171A vizsgált kezelés

    Single dose of HW281171 tablets

    Kezelés: HW281171 tablets

  • Part A:PlaceboPlacebo, összehasonlításként

    Single dose of Placebo tablets

    Kezelés: Placebo tablets

  • Part B:Sequence AA vizsgált kezelés

    Single dose of HW281171 tablets under fasting-fed sequence

    Kezelés: HW281171 tablets

  • Part B:Sequence BA vizsgált kezelés

    Single dose of HW281171 tablets under fed-fasting sequence

    Kezelés: HW281171 tablets

  • Part C:HW281171A vizsgált kezelés

    Multiple doses of HW281171 tablets

    Kezelés: HW281171 tablets

  • Part C:PlaceboPlacebo, összehasonlításként

    Multiple doses of Placebo tablets

    Kezelés: Placebo tablets

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Profiles of Single and Multiple Oral Administration and Dose Escalation of HW281171 Tablets in Healthy Participants
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
Illeszkedési kérdések
Forrás: NCT07936032: ki vehet részt
A regiszteradat frissítve
2026. november 13.